The role of imaging with iodine-131-meta-iodobenzylguanidine in the diagnosis and localisation of suspected phaeochromocytoma by Adams, B K
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
THE ROLE OF IMAGING WITH IODINE-131-META-IODOBENZYLGUANIDINE 
IN THE DIAGNOSIS AND LOCALISATION OF SUSPECTED 
PHAEOCHROMOCYTOMA 
1987 
DR B.K. ADAMS 
The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
Published by the University of Cape Town (UCT) in terms 
of the non-exclusive license granted to UCT by the author. 
Un
ive
rsi
ty 
f C
ap
e T
ow
n
IN FULFILMENT OF THE REQUIREMENTS 
FOR TUE DEGREE OF MASTER OF MEDICINE 
IN TUE DEPARTMENT OF NUCLEAR MEDICINE 
AT THE 
UNIVERSITY OF CAPE TOWN 
i 
ACK N 0.WJ,_g_p G E_M.~N.T S 
I wish to thank those who have helped me with this project. 
I am especially indebted to: 
Dr J.A.Smith, Head of the Department of Nuclear Medicine, 
for his guidance and criticism. 
Dr A.Fataar, Consultant in the Department of Nuclear 
Medicine, for his assistance and encouragement. 
Professor F.Bonnici, Professor of Paediatrics, for his 
guidance and supervision. 
Mr J.Boniaszczuk, senior radiographer in the department, for 
his assistance. 
Ors P.Jennings and S.Dowdle, registrars in the department, 
for their support. 
The Radiographers in the department who performed the 
scintigraphy. 
Ms J.Kent, secretary in the department, for her assistance. 
Ms F.Isaacs, secretary of the Clinical Photography 
Department for her assistance. 
The rest of the staff in the Department of Nuclear Medicine 
for their support. 
ii 
CONTENTS 
INTRODUCTION ••••••••••••••••••••••••••••••••••••••••••• 1 
CHAPTER ONE 
FEATURES OF PHAEOCHROMOCYTOMA •••••••••••••••••••••••••• 3 
Origin and Distribution •••••••••••••••••••••••• 3 
Incidence •...•...••.••...••.••....••••••••••••• 4 
Biochemistry . . . . • . • . . • . • 5 
Clinical Features • • • • • • • • • • • • 7 
Diagnosis 
Management 
CHAPTER TWO 
• • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • 8 
• • • • • • • • • • • • • . • • • • • . • • • . • . • . • • • • • • 1 3 
131!-MIBG META-IODOBENZYLGUANIDINE •••••••••••••••••••• 14 
Chemistry •..••.•.•••...•••......••..•..•..••. . 14 
Metabolism ••••••••••••••••••••••••••••.••••••• 16 
Mechanism of Uptake ••••••••••••••••••••••••••• 18 
Dosimetry ............ • .. ...••..........•.•..... 19 
131I-MIBG SCINTIGRAPHY •••••••••••••••••••••••••••••••• 20 
Patient selection ............................ . 20 
Imaging protocol and Technique •••••••••••••••• 21 
Imaging patterns .............................. 21 
Normal distribution ••••••••••••••••••••••••••• 21 
Abnormal Uptake ••••••••••••••••••••••••••••••• 25 
ROLE OF 123I-MIBG SCINTIGRAPHY •••••••••••••••••••••••• 26 
NONPHAEOCHROMOCYTOMA IMAGING •••••••••••••••••••••••••• 27 
i i i 
CHAPTER THREE 
THE USE OF 131I-MIBG AT GROOTE SCHUUR HOSPITAL •••••••• 29 
MATERIALS AND METHODS • • • • • • • • • • • • • • • • • • • • • • • • • 2 9 
Administration •...•••...•••.••.••• 29 
Acquisition ...•.••...•••••••••• 30 
Data analysis ................................ . 31 
RESULTS • • • • • • • • • • • • • • • • . • • . • • • . . • • • • • • • • • • . • 3 1 
Totals •••••••••• 32 
Sensitivity •••••••••••• 32 
Specificity ................................... 33 
POSITIVE 131I-MIBG SCINTIGRAMS •••••••••••••••••••••••• 33 
1. Clinical Features •••••••.•••••••••••••••••• 33 
2. Biochemical Findings ••••••••••••••••••••••• 34 
3. Computerised Tomography •••••••••••••••••••• 36 
4. Types of Phaeochromocytoma ••••••••••••••••• 36 
NEGATIVE 131I-MIBG SCINTIGRAMS •.....•..•••.•.• 38 
1. Clinical Features ....•••.••..••.. 38 
2. Biochemical Findings ••••••••••••••••••••••• 39 
3. Computerised Tomography and Ultrasound ••••• 39 
INDETERMINATE SCINTIGRAMS ••••••••••••••••••••••••••••• 40 
1. Clinical Features •••••••••••••.•••••••••••• 40 
2. Biochemical Findings ••••••••••••••••••••••• 40 
3. Computerised Tomography •••••••••••••••••••• 40 
iv 
CHAPTER FOUR 
DISCUSSION ~ • • • . • • • • . • • • • • • • • • • • • • • • • . • • • • • 4 6 
Sensitivity .................................. . 46 
Specificity ..........•.................•..... . 49 
TRUE POSITIVE SCINTIGRAMS ••.•••••••.•••••••••••••••••• 49 
Biochemistry ................................. • 49 
Clinical Patterns . • • • • • • • • • 5 1 
Types of Phaeochromocytoma •••••••••.• 52 
TRUE NEGATIVE SCINTIGRAMS ••••••••••••••••••••••••••••• 55 
THERAPY WITH 131I-MIBG ••.•.••••.•.•••••••••••••.•.•••• 55 
CONCLUSION ................................• 58 
REFERENCES •••••••••••••••••••••••••••••••••••••••••••• 60 
V 
LIST OF FIGURES AND TABLES 
FIGURE 1 •••••••••••••••••••••••••••••••••••••••••••••• • 6 
Biosynthesis and metabolism of catecholamines 
FIGURE 2 ••••••••••••••••••••••••••••••••••••••••••••• • 15 
Structures of norepinephrine, guanethidine and MIBG 
TABLE 1 ••••••••••••••••••••••••••••••••••••••••••••••• 12 
Biochemical tests for phaeochromocytoma and 
interfering substances 
TABLE 2 •••••••••••••••••••••••••••••••••••••••••••• 4 2 -4 5 
Results 
PIE CHART ••••••••••••••••••••••••••••••••••••••••••• • 32a 
HISTOGRAMS 
Positive 131I-MIBG scintigraphy •••••••••••••••••••••• 37a 
Histologically proven cases ••• ; •••••••••••••••••••••• 37b 
Negative 131I-MIBG scintigraphy •••••••••••••••••••••• 39a 
Indeterminate 131I-MIBG scintigraphy ••••••••••••••••• 41a 
Summary of patient features •••••••••••••••••••••••••• 41b 
INTRODUCTION 
TH_E ROLE OF ___ ! MAG_I_NG ____ W_I T_H ____ __IODI N_E-_1_31-M_E_TA- I ODOBENZ YLGU A_NI_D !_NE 
I_N _T_l:-lE ___ o J:.A.GNOS_I __ s ___ ANO_ LOC_AL I S_AT I ON __ O_F _s_u s P_E_CT EP 
PHAEOCHROMOCYTOMA 
Phaeochromocytoma is a potentially lethal disorder. The 
secretion of increased amounts of catecholamines into the 
circulation by the metabolically active tumour can be life-
threatening. Both benign and malignant tumours have this 
capability. Surgical removal of the majority of these 
tumours (other than the malignant, metastastic ones) is 
curative. Thus the detection and localisation of the 
phaeochromocytoma are vitally important. 
The decade of the 1980's saw the development of 131r-
meta-iodobenzylguanidine(13lr-MI8G),a radiopharmaceutical 
reported to allow for the scintigraphic detection and 
localisation of the phaeochromocytoma. Wieland and his 
colleagues at the University of Michigan Medical School 
produced images of the adrenal medullas of dogs and monkeys 
using 131!-MIBG.1;2 Sissons et al working at the same 
medical school produced the first scintigraphic images in 
patients soon afterwards.3 They claimed that scintigraphy 
was both safe and reliable for the localisation of 
phaeochromocytomas. Subsequent studies appear to have 
confirmed this initial impression.4;5;6;7;8 
1 
This study is an evaluation of the role of 1311-MIBG 
scintigraphy and the results of our experience at the Groote 
Schuur Hospital over the last 4 years. The study entailed a 
review of literature on phaeochromocytomas, the 
characteristics of 1311-MIBG and its scintigraphic 
appearances. In addition, a retrospective study of patient 
records is presented. The clinical, biochemical and 
scintigraphic features of the patients are compared with 
with the findings of other researchers in this field. 
) 
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CHAPTER ONE 
FEATURES OF PHAEOCHROMOCYTOMA 
ORIGIN AND DISTRIBUTION 
Phaeochromocytomas arise from chromaffin cells.These cells 
are of neuroectodermal origin. In the first trimester of fetal 
life, cells of the neural crest migrate from the thoracic region 
to form the sympathetic chain and to invade the developing 
adrenal cortex, where they become the adrenal medulla. 
Chromaffin cells are widespread during fetal life but degenerate 
from the age of three years. The major residual clusters of 
chromaffin cells comprise the adrenal medulla. 
Thus approximately 90% of phaeochromocytoma arise from the 
adrenal medulla. Extra-adrenal phaeochromocytomas are found in 
sites ranging from the carotid body to the pelvic floor. The 
majority are associated with paravet'tebral sympathetic ganglia, 
the organ of Zuckerkandl near the aortic bifurcation in the 
abdomen, and with ganglia in the posterior mediastinum. These 
extra-adrenal phaeochromocytomas are more likely to be malignant 
than adrenomedullary phaeochromocytomas. 
Cryer9 and others10 refer to a 11 extra-adrenal 
phaeochromocytomas as paragangliomas while Smit et a1ll uses the 
term, paraganglioma when the tumour is extra -adrenal and 
nonfunctional but prefers the term, phaeochromocytoma for tumours 
3 
which secrete catecholamines, whether they are intra- or extra-
adrenal. Khafagi12, on the other hand, reserves the term 
phaeochromocytoma for functional tumours of the adrenal medulla, 
and uses "functional" and "nonfunctional" paragangliomas for 
extra-adrenal tumours according to whether or not they secrete 
catecholamines and produce "the clinical syndrome of 
phaeochromocytoma". 
In this paper, all chromaffin tumours (with the exception 
of Carcinoid tumours which arise from enterochromaffin cells) are 
referred to as phaeochromocytomas, and specific mention is made 
as to whether these are adrenomedullary or extra-medullary and 
whether they are metabolically active or not. 
cases. 
Multiple phaeochromocytomas occur in up to 10% of sporadic 
However, bilateral adrenomedullary phaeochromocytomas are 
the rule in familial phaeochromocytoma associated with multiple 
endocrine neoplasia (MEN) type 2a and type 2b syndromes. MEN 2a 
(Sipple's syndrome) includes medullary carcinoma of the thyroid, 
primary hyperparathyroidism 
includes medullary carcinoma of 
neuromas and phaeochromocytoma. 
and phaeochromocytoma. MEN 2b 
the thyroid, multiple mucosa! 
Familial phaeochromocytomas also 
occur in association with neurofibromatosis 
Hippel-Lindau syndrome. 
and in the van 
INCIDENCE 
The incidence of phaeochromocytoma in the adult population has 
4 
been reported as being between 0.01% and 0.001%.13,14 The 
incidence in hypertensive patients is thought to·be in the order 
of 0.1%-0.01%.14 Approximately 10% occur in children, 10% are 
extraadrenal and 10% are malignant13 .Sutton15 in a series of 
autopsy-proven cases discovered that the disorder was multiple in 
19%, extra-adrenal in 9% and malignant in 11%. 
Phaeochromocytomas present most commonly in the fourth and fifth 
decades when they occur predominantly sporadically. Multi focal 
tumours occur in 35% of children. No sex predominance has been 
noted. 
BIOCHEMISTRY 
The substrate of catecholamine synthesis is tyrosine which 
is hydroxylated to L-DOPA (Oihydroxyphenylalanine). The enzyme 
PNMT (Phenylethanolamine methyl transferase) converts 
nor-epinephrine to epinephrine. (See Figure 1 on page 
Epinephrine is the major hormonal product in the adrenal medulla. 
Nor-epinephrine 
endings. 
acts as a neurotransmitter at sympathetic nerve 
Nor-epinephrine and epinephrine are stored in granules 
which release their contents when the sympathetic nervous system 
is activated.These catecholamines are inactivated by re-uptake 
and by metabolic degradation. Metabolites include VMA 
(vanillylmandelic acid), metanephrine and NMA (normetanephrine). 
Free catecholamines and their metabolites are excreted in the 
urine. Nor-epinephrine may be excreted by intra- and extra-adrenal 
tumours, whereas 95% of epinephrine-secreting tumours are intra-
5 
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CLINICAL FEATURES 
The clinical manifestations of phaeochromocytomas are due 
mainly to the effects of the catecholamines they 
Phaeochromocytomas release noradrenaline predominantly, 
produce. 
but some 
adrenaline is also released. Rarely do the mass effects of the 
tumour give rise to symptoms. Some phaeochromocytomas are 
discovered at autopsy or incidentally at surgery. A review of 
autopsy-proven cases of phaeochromocytoma seen at the Mayo Clinic 
over a 50 year period showed that only 24% of patients were 
correctly diagnosed in life.15 
Common symptoms of phaeochromocytomas are headache, 
palpitations, diaphoresis and anxiety. Other symptoms include 
abdominal or chest pain, gastrointestinal symptoms, weakness or 
visual symptoms. Symptoms are typically paroxysmal and associated 
with increases in blood pressure. Paroxysms usually last only a 
few minutes but may persist for up to an hour or more. 
Hypertension is often sustained but may be intermittent. 
Persistent hypertension is found in 55%13,15 of patients. In 
these cases there may be marked fluctuations in the blood 
pressure with peaks occurring during symptomatic episodes. These 
7 
episodes are explained on the basis of intermittent catecholamine 
release- plasma r.atecholamine levels are higher during 
hypertensive episodes than during asymptomatic, less hypertensive 
or normotensive intervals. What precipitates the episodic 
catecholamine release is unknown and the relationship between 
plasma noradrenaline levels and blood pressure is not a constant 
one.16 
Convulsions, visual disturbances, weight 
vomiting all occur more frequently in children13. 
Metabolic features of phaeochromocytoma 
increased metabolic rate patients may complain 
loss, 
include 
of 
and 
an 
heat 
intolerance and weight loss ), limitation of insulin secretion 
and an insulin resistant state. 
overt diabetes is unusual. 
Glucose intolerance occurs but 
The rare, predominantly adrenaline-releasing phaeochromocytomas 
can produce different paroxysms. These may include systolic 
hypertension, tachycardia, hypotension, non-cardiac pulmonary 
oedema and cardiac arrythmias. 
DIAGNOSIS 
Phaeochromocytomas produce catecholamines which give rise 
to typical symptoms when released into the circulation. The 
diagnosis of 
dependent upon 
a clinically suspected phaeochromocytoma is 
the detection of these catecholamines and their 
metabolites in the plasma and urine. The most widely used 
8 
screening procedures for the detection of phaeochromocytoma are 
measurements of urinary catecholamines or their metabolites, such 
as vanillylmandelic acid (VMA) or total metanephrines. However, 
some feel that these tests are erratic and plasma catecholamine 
concentrations have been found to be more reliable predictors of 
phaeochromocytoma.16 
The diagnosis of phaeochromocytoma is suspected on the 
basis of clinical manifestations and is confirmed biochemically. 
Phaeochromocytomas are suspected in patients with paroxysmal 
symptoms and hypertension that is intermittent, labile or 
resistant to conventional therapy. Persons with a familial 
history of phaeochromocytoma should be thoroughly evaluated. 
Nuclear medicine and radiographic studies are used to confirm the 
diagnosis and localize phaeochromocytomas once the diagnosis is 
strongly 
evidence. 
suspected on 
Fluorometric 
the basis 
assays 
of clinical and biochemical 
of catecholamines or 
spectrophotometric measurement of total metanephrines or VMA in 
24-hour urine collections are the most common approach to the 
biochemical diagnosis of phaeochromocytoma. The urinary 
catecholamines can be fractionated into adrenaline and 
noradrenaline if predominant adrenaline release is suspected. The 
excretion of all these substances is significantly increased in 
the majority of patients with phaeochromocytoma.14 Catecholamine 
excretion is an index of released catecholamine whereas 
9 
catecholamine degradation within the tumour also 
the excreted VMA. 
contributes to 
The development of 
and dual radioisotope methods 
highly sensitive and specific single 
for plasma catecholamine assays 
has resulted in these being used in the diagnosis of 
phaeochromocytoma in certain institutions.16 These assays obviate 
the need to collect 24-hour urine specimens; blood can be 
conveniently collected before and after a provocative test, and 
catecholamine levels correlated with blood pressure response; and 
spontaneous or provoked changes in catecholamine production can 
be correlated with cardiovascular status. However, care must be 
taken to ensure that the patient is in a resting state when the 
blood is taken as even minimal stress can result in an elevation 
of catecholamine levels. 
Bravo and his colleagues16 use the following diagnostic approach: 
1. total plasma catecholamine levels are measured with the 
patient at rest and in a supine position. A value of 1000 ng per 
litre or less rules out phaeochromocytoma and values between 1000 
and 2000 ng per litre are equivocal. 
2 • a glucagon test is performed only if the clinical findings 
are highly suggestive of phaeochromocytoma. A positive glucagon 
test requires a rise in the systolic blood pressure of at least 
15-20 mm Hg above the response to a cold pressor test, and a 
clear increase (at least threefold or greater than 2000 ng per 
10 
litre) in simultaneously measured plasma catecholamines. However, 
provocative tests like these are dangerous and are rarely used 
for diagnostic purposes today. 
Bravo and his colleagues16 claim that the plasma 
catecholamine measurements are superior to measurements of 
urinary catecholamines because there is less overlap between 
affected and unaffected hypertensive patients. But the two 
yield different information. Urinary measurements approaches 
provide an index of catecholamine production and release over a 
period of 24 hours. They might reflect intermittent catecholamine 
elevations that could be missed by plasma measurements which 
provide information relevant to a comparatively short time period 
of a few minutes. 
Careful sample collection, handling and 
essential for reliable results. A knowledge of the 
storage are 
sources of 
biological variation of catecholamines and the effects of drugs 
is vital if diagnostic error is to be 
page 12)13 
avoided.(See Table 1 on 
It must however be emphasised that most patients with 
phaeochromocytomas have elevated plasma and urinary catecholamine 
levels. 
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TABLE l 
URINARY 
Normal values 
G.S.H. 
Increase 
Decrease 
BIOCHEMICAL TESTS FOR PIIEOCIIROMOCYTOMA ANO 
INTERFERING SUBSTANCES 
VMA ME T /\ N E P 11.R I N E S C/\TECHOLI\MINES 
< 6.5 mg/24 h < 1. 3 mg{24 h < 100 ug/ 24h 
0...:40 µmol/24h 0--5 µmol/24h E < 20 ug/24h 
NE< 80 ug24h 
Catecholamines Catecholamines Catecholamines 
Drugs containing Drugs containing Drug containing 
catecholamines catecholamines catecholamines 
Amphetamines 
' 
Amphetamines /\mphetamines 
Methyl dopa Methyl dopa Methyl dopa 
Levodopa 
Clonidine Clonidine Clonidine 
withdrawal withdrawal withdrawal 
Ethanol Ethanol 
Methacarbanol Diatrizoate Erythromycin 
Glyceryl g~aiaco- M/\0 inhibitors Tetracycline 
late 
Nalidixic acid Chlorpromazine 
Quinine 
Metyrosine Metyro~ine Metyrosine 
Reserpine Reserpine Reserpine 
Guanethidine Guanethidine Guanethidine 
MAO inhibitors 
Clofibrate 
Di su lfi ram 
Ethanol 
E, epinephrine: NE, norepinephrine 
12 
MANAGEMENT 
The tr-eatment of choice for- unifocal and multifocal 
phaeochr-omocytoma is sur-gical r-emoval. For surgery to be 
successful localisation of all existing tumour sites is 
essential. Computerised tomography (CT) is very sensitive for 
diagnosing intraadrenal phaeochromocytomas over 2 cm in size. 
However, smaller lesions and extraadrenal foci may defy 
identification by CT.B,17 Even if CT delineates an extraadrenal 
tumour, the nature of the anatomic abnormality remains uncertain. 
1311-MIBG Scintigraphy was intr-oduced by Sissons and his 
colleagues3 in 1981 as a non-invasive whole body screen for 
imaging and localising phaeochromocytoma. They claimed that: 
"Scintigrams are appealing because they not only 
locate the anatomic position of the disease but also shed light 
on the nature of the disturbance by providing evidence of, 
function." 
They also noted that 1311-MIBG localised in malignant as 
well as benign phaeochromocytomas. 
13 
CHAPTER TWO 
13_1_I -MET_A- I ODOBENZ YLGUAN_I D_lNE 
131I-MIBG was 
medulla in 1981.3 
first used to image the human adrenal 
Sisson and his colleagues3 produced 
images of phaeochromocytomas in 8 patients with known 
tumours using 1311-MIBG although the normal adrenal medulla 
was not visualised. 
CHEMISTRY 
131I-MIBG is a radioiodinated aralkylguanidine and an 
analogue of norepinephrine and guanethidine(a potent 
adrenergic neuron blocking agent).(See Figure 2 on page15)13 
It was first synthesised by Wieland et al in 1979.18 The 
meta- isomer showed less liver and thyroid uptake indicating 
that it was more stable in vivo than the para-isomer.1;2 
Subcellular fractionation of the adrenal medulla showed 
sequestration of 1311-MIBG in the chromaffin granules.2 
MIBG is reacted with cyanamide and dissolved in 
potassium bicarbonate to precipitate MIBG bicarbonate. This 
is then reacted with normal sulphuric acid and purified by 
recrystallization to form MIBG sulphate as colourless 
crystals. Radioiodination is achieved with 123I, 125I or 
131I. A radiochemical yield of 60%-80% is achieved and 
14 
FIGURE 2 
HO lQJ CHCH 2NH2 0 bH 
HO 
NORE PINE PHRINE 
0 N"'H II N-CH 2CH 2NH-C- NH 2 
GUANETHIDINE 
· Fig 2 Comparison of the structurs of norepinephrine, 
guanethidine, and rneta-iodobonzylguanldine. 
. . . 
15 
specific activities up to 370 Mega Becquerels(MBq)/mg (10 
mCi/mg).1 Specific activities in excess of 1480 MBg (40 mCi) 
/mg have now been achieved for therapeutic purposes.13 
Amino-iodobenzylguanidine, an analogue of MIBG, has been 
developed.19 This agent is reported to show an affinity for 
the heart and adrenal medulla which is similar to that of 
MIBG in dogs and monkeys. It is available in a kit-form but 
has not yet been tested in humans. 
MIBG shares the same mode of uptake and retention as 
norephrine in peripheral adrenergic nerves.In vitro studies 
have shown that MIBG is avidly sequestered by the uptake 
carrier that transports norepinephrine •. Sisson et al3 showed 
that the percentage of the dose of 1311-MIBG accumulating in 
phaeochromocytomas was 2% or less. They found no correlation 
between this percentage and the types or magnitudes of 
hormones in plasma and urine, or with the concentrations of 
norepinephrine and epinephrine within the tumours. Mangner 
et a120 found that 97% to 100% of the radioactivity 
extracted from the tumours of two patients was in the form 
of 1311-MIBG. One tumour contained a small amount of free 
radio iodide. 
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Mangner et a120 evaluated the excretion and metabolism 
of 131!-MIBG in nine patients with phaeochromocytomas. They 
found that the major route of excretion is by the urinary 
tract. Forty to 55% of the administered activity appeared in 
the urine within 24 hours and 70% to 90% was recovered 
within 4 days. Using reverse high performance liquid 
chromatography they discovered unaltered 1311-MIBG to be the 
major radioactive urinary component, accounting for 75% to 
90% of the total radioactivity in 8 of the 9 patients 
investigated. 131!-iodide and 1311-m-iodohippuric acid were 
minor components in the urine samples. They found no 
correlation between plasma or urinary catecholamine levels, 
the presence of urinary metabolites and the location of 
tumours.20 Less than 1% of the administered dose was 
detected in the faeces.20 
These findings suggest that 131!-MIBG is not 
appreciably metabolized and that it is excreted by the 
kidneys primarily as the unaltered compound. Furthermore, 
the analysis of the radioactivity extracted from the 
phaeochromocytomas following 1311-MIBG administration 
indicates that MIBG is solely responsible for the images 
observed in humans. 
17 
MECHANISM_ OF ___ U_PT AK_E 
1311-MIBG localizes within the intracellular, storage 
granules of the sympatho-adrenal system. The mechanism of 
to be clearly defined uptake remains 
cultured human 
adrenomedullary 
phaeochromocytoma cells 
but experiments with 
and cultured bovine 
cells have indicated that this occurs 
through the sodium-dependent Type 1 catecholamine uptake 
mechanism.21;22 This uptake mechanism is shared by 
norepinephrine which is a competitive inhibitor of MIBG. 
Uptake is characterised by high affinity, low capacity, 
saturability, temperature, and ouabain sensitivity.21 It is 
an active process which is inhibited by desmethylimipramine 
and cocaine.22 
Shapiro et al 4 investigated 400 patients with 
phaeochromocytoma and discovered that the uptake of 1311-
MIBG by phaeochromocytoma is variable and ranges from no 
detectable activity (and hence false negative scans) through 
minimal uptake to intense uptake (true positive).These 
patterns occur in tumours which are apparently 
indistinguishable from each other in terms of location, 
histology, and levels of plasma and urinary catecholamine. 
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The uptake and storage mechanism of 131r-MIBG does not 
always parallel the synthesis and secretion of 
catecholamines. 
DOSlMETRY 
Dosimetry calculations in humans are based upon tissue 
distribution data derived from experimental work on rats. It 
has been calculated that the largest absorbed dose from 
131r-MIBG is delivered to the adrenal gland.13 The adrenal 
medulla is subjected to an estimated 100 rad/37 MBq(mCi) of 
1311-MIBG. The use of 1231-MIBG significantly reduces the 
radiation dose to 0.8 rads/37 MBq for "pure" 1231-MIBG. 
However 125r contamination of 123_r increases the dose to 
the adrenal medulla to 2.76 rads/37 MBq, that is by a factor 
of 3.5.13 
A radiation dose of approximately 35 rads/37 MBg is 
delivered to the unblocked thyroid gland by 1311-MIBG. This 
emphasises the importance of effectively blocking thyroid 
uptake. Far lower dosimetry estimates have been made for the 
heart (0.7 rads/37 MBg), liver (0.40 rads/37 MBq), ovaries 
(1.0 rads/37 MBq) and spleen (1.6 rads/37 MBg).13 The total 
body absorbed dose has been estimated at 0.1 rads/37 MBq for 
131!-MIBG and 0.02 for 123r-MIBG.13 
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13 l_I -MI BG ___ SCI NT_I_GRA_PHY 
PATIENT SELECTION 
There should be a strong suspicion of phaeochromocytoma 
before a patient is selected for 131!-MIBG scintigraphy. 
Shapiro et al4 use the following criteria: 
1. Labile, severe or uncontrolled hypertension and/or 
2. Spells manifested by headache, palpitations, sweating, or 
abdominal pain and/or 
3. Basal plasma norepinephrine.)600 pg/ml and epinephrine 
>150 pg/ml or 
4. Persistent urinary excretion rates for catecholamine that 
are greater than 3 s.d. above the mean for normal subjects. 
5. Patients in whom there is historical, clinical or 
laboratory evidence of a syndrome associated with an 
increased frequency of phaeochromocytoma but who manifest 
only minor symptoms and/or intermittent or borderline 
laboratory abnormalities of phaeochromocytoma. 
In their series of 400 patients , Shapiro and his 
colleagues found no evidence of phaeochromocytoma in 
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patients with symptoms not typical of phaeochromocytoma and 
with normal catecholamine levels. 
Indications13 for imaging include: 
1. Confirmation of adrenal disease if CT is equivocal; 
2. Excluding coexisting extra-adrenal disease; 
3. Identification of recurrent or extra-adrenal tumours; 
4. Detection of unsuspected multifocal disease; 
5. Assessment of malignant phaeochromocytoma; 
6. Investigation of patients with a strong family history of 
phaeochromocytoma. 
IMAGING PROTOCOL __ AND __ TECHNIQ_U .. E 
This aspect is discussed in detail in Chapter 3. 
IMAGING_ PATTERN_S 
NORMAL DI_STRI.BUTION 
A thorough knowledge of the normal distribution of 
131I-MIBG is essential for the correct interpretation of the 
scintigraphs. 
21 
ADRENAL MEDULLA 
The normal adrenal medulla is not visualized by 1311-
MIBG in the majority of patients but there have been reports 
of faint uptake in a few patients.25 1231-MIBG scintigraphy, 
however, permits the routine visualization of normal adrenal 
medulla.23;24 This is due to the fact that the 1231-MIBG 
dose used is 20 times greater than that of the 1311-MIBG. 
LIVER 
There is uniform uptake of 1311-MIBG by the liver which 
is maximal at 24 hours and clears substantially by 72 
hours.13 The liver activity declines more rapidly than most 
phaeochromocytomas thus reducing the chances of the liver 
activity obscuring a phaeochromocytoma. 
SPLEEN 
The rich sympathetic innervation of the spleen results 
in early uptake which clears over 72 hours. 
URINARY BLADDER 
The renal excretion of 1311-MIBG results in bladder 
activity which may obscure extraadrenal phaeochromocytoma in 
the bladder or pelvis. Despite the fact that 55% of injected 
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activity is excreted within 24 hours the bladder must be 
emptied prior to performing pelvic scintigraphy.13 
LARGE BOWEL 
Large bowel uptake has been found in up to 20% of 
studies.25 The mechanism of uptake is uncertain but activity 
is known to increase in severe constipation and in renal 
insufficiency. Gut uptake may be sufficient to obscure or be 
confused with tumour uptake. 
SALIVARY GLANDS 
Their rich sympathetic innervation allows for the 
salivary glands to be visualized in almost all patients. The 
mechanism of uptake 
uptake.25 
is thought to be due to neuronal 
HEART 
Cardiac visualisation of 1311-MIBG is variable and 
Nakajo et a125 has shown that the intensity of uptake is 
greater in patients with no phaeochromocytoma. Cardiac 
uptake is due to its rich sympathetic innervation. Some 
suggest that visualization of the myocardium at 24 hours 
makes the diagnosis of phaeochromocytoma unlikely.13 
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1231-MIBG uptake by the heart is sufficiently high for 
this agent to be used for myocardial scintigraphy.26 
LUNGS 
High uptake is present within 2 hours of administration 
of the radiopharmaceutical but this disappears rapidly and 
does not interfere with inter- pretation. Nakajo et a125 
found that the lower lobes of the lungs are visualised more 
frequently (in 68% of normals) than the middle lobes (in 24% 
of normals). The upper lobes were visualised in only 2% of 
normals. They feel that these differences in frequency and 
intensity of uptake may be due to the relative lung volumes 
and vascularity in these zones. 
THYROID 
If the thyroid gland is adequately blocked before the 
administration of 1311 -MIBG visualization of the gland is 
uncommon. 
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ABNORMAL UPT_AKE 
PHAEOCHROMOCYTOMA 
Phaeochromocytomas are characterized by their ability 
to concentrate 1311-MIBG and are visualized as foci of 
increased uptake 
adrenally. 
whether they are situated intra- or extra-
Phaeochro~ocytomas metastases are identified for the 
same reason. The commonest site of metastatic spread is to 
bone. 1 3 Liver metastases have also been reported.13 Follow-
up bone and liver scintigraphy is useful for determining the 
spread of the disease.5 Both benign and malignant tumours 
concentrate the 131r-MI8G and scintigraphy. is unable to 
distinguish between these. Scintigraphy therefore screens 
for multifocal or bilateral disease and metastases. 
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THE ROLE OF 1231-MIBG SCINTIGRAPHY 
. . - . - . 
Lynn23 and Shapiro24 have found 1231-MIBG to be 
superior to 1311-MIBG as an imaging agent. 370 MBq (10 mCi) 
of 1231-MIBG have a radio-dosimetry similar to that of 18.5 
MBq (0.5 mCi) of 1311-MIBG and provide a greater, more 
useful (159 KeV energy) photon flux. They have shown a 
better delineation of lesions and the detection of smaller 
lesions.23;24 Lynn demonstrated 3 lesions on 1231-MIBG which 
were not visualised on the 1311-MIBG images.23 Shapiro 
demonstrated additional lesions in 5 of 19 patients in whom 
a comparative study was done.24 They performed successful 
single photon emission tomography 
patients using 123r-MIBG.24 
(SPECT) studies on 8 
In addition 1231-MIBG permits the visualisation and 
quantification of uptake in the normal adrenal 
medulla.23;24;27 Bomanji 
hypertensive patients 
et a127 using 1231-MIBG in 18 
who had no evidence of phaeo-
chromocytoma visualised the adrenal medullas in all the 
patients except one. They quantitated the uptake in the 
adrenal medullas and found a range of 0.01-0.22% of the 
administered dose.27 
Some feel that 1231-MIBG should be used in the 
investigation of patients in whom clinical suspicion is high 
but who have negative or equivocal 1311-MIBG scintigraphy.4 
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However, 1231 is far more costly and less readily available 
for general use. 
NONPHAEOCHROMOCYTOMA_IMAGING 
1311-MIBG uptake has been found to occur in a range of 
neuroendocrine tumours (apudomas) including neuroblastoma, 
carcinoid tumours, 
thyroid.28-37 
NEUROBLASTOMA 
and medullary carcinoma of the 
A number of reports have noted the excellent uptake of 
131!-MIBG by neuroblastomas.28-31;33 Munkner28 has shown 
that this technique is highly sensitive for the detection of 
local and extensive disease. Ikekubo et a129 used 1311-MIBG 
to locate both the primary abdominal tumour and a distant 
metastatic orbital tumour. 
significant resolution of 
treatment.29 Hoefnagel et al 
Imaging 
these 
also 
tumours 
demonstrated 
following 
detected neuroblastomas in 47 
patients using 1311-MIBG, and found the investigation to be 
95% sensitive and 100% specific.30 
The use of 1311-MIBG as a therapeutic agent for this 
condition is being investigated in a number of centres. 
Huberty31 and his colleagues are using this method in 
children with stage IV disease who have failed conventional 
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therapy but it is still too early to assess the efficacy of 
this therapy. 
CARCINOID TUMOUR 
1311-MIBG uptake by carcinoid tumours have been 
reported.30;32;34;37 Hoefnagel and his colleagues32 report a 
case of metastatic gastric carcinoid tumour concentrating 
the radiopharmaceutical. Both the primary tumour and the 
liver mets were detected by 1311-MIBG. Fischer et a134 also 
showed the presence of liver metastases using 1311-MIBG. 
Hoefnagel et a130 demonstrated carcinoid tumours in 6 of 12 
patients with this disorder. Feldman et al visualised 
carcinoid tumours· in 14 of 23 patients with these tumours 
and they made the observation that the 1311-MIBG 
concentrated most avidly in tumours of ~idgut origin.37 
MEDULLARY CARCINOMA OF THE THYROID 
Troncone et a135 demonstrated uptake in both the 
primary tumour and metastases in patients with medullary 
carcinoma of the thyroid. 
uptake in this carcinoma 
syndrome. 
Ansari et a136 report 1311-MIBG 
in a patient with type 2b MEN 
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CHAPTER THREE 
THE _USE __ OF __ 13_1I-MIBG ___ AT_ GROOTE _____ SCHUUl3 _JjQSPI._'.Lb.h!. 
A total of 28 patients had 131I-MIBG scintigraphy at 
GSH during the period from mid-1983, when this investigation 
was first instituted, to 1987. The study is a retrospective 
one and includes a review of patient clinical records and 
scintigrams. 
MA_TERI_ALS __ AND ___ METHODS 
had 1311-MIBG scintigraphy. Twenty-eight patients 
Thyroidal uptake of 1311 was blocked by Lugol's iodine 
solution, 30 mg per day, given 24 hours before the 
administration of the radiopharmaceutical. This treatment 
was continued for a minimum of 5 days. 
Drugs like reserpine, the tricyclic antidepressants and 
phenylpropanolamine preparations were stopped at least a 
week prior to scintigraphy as they interfere with the uptake 
of 131I-MIBG.3;13 
ADMINISTRATION 
18.5 MBq of 131I-MIBG obtained from the Atomic Energy 
Corporation was administered by slow intravenous infusion 
over 20 to 30 seconds as the possibility of a hypertensive 
• 
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crisis exists due to norepinephrine displacement from the 
storage granules. The patients were monitored for 
alterations in vital signs for at least 30 minutes following 
the injection. 
The unfavourable radio-dosimetry of 1311-MIBG limits 
the dose to 18.5 MBq/1.7m2. 370 MBq of 1231-MIBG has the 
equivalent dosimetry and gives superior images. 
ACQUISITION 
Images were obtained using an Elscint Apex 415 gamma 
camera with a medium energy, high sensitivity, parallel hole 
collimator. Imaging 
the administration 
was performed at 24 and 48 hours after 
of the 131I-MIBG. Multiple posterior 
overlapping views of at least 50 000 counts from the skull 
to the bladder were obtained. Anterior and lateral views 
were obtained when it became necessary to localise lesions. 
As the bulk of the 131I-MIBG excretion occurs via the 
urinary tract, the bladder was emptied before the pelvis was 
scanned to avoid confusion. 
Anatomical orientation and localisation of the 
sequential images was achieved by simultaneous scintigraphic 
demonstration of the kidneys using technecium-99m (99mTc) 
labelled diethylenetriaminepentacetic acid (DTPA). 
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DATA ANALYSIS 
The scintigrams were evaluated by experienced nuclear 
medicine physicians. This was followed by a review of the 
medical records of the patients for urinary and plasma 
catecholamine and VMA and NMA levels all measured by the 
previously described methods. The clinical histories of the 
patients were scrutinised and the results of radiological 
studies e.g. 
reviewed. 
computerised tomography and ultrasound were 
Clinical, biochemical and scintigraphic data on each 
patient are tabulated below. 
divided into: 
Scintigraphic results were 
1. POSITIVE: where there is a clearly defined 
abnormal focus or foci. 
2. NEGATIVE: where there is no. evidence of an 
abnormal focus. 
3. INDETERMINATE: where an ill-defined area of 
low-intensity makes a definitive diagnosis difficult or, 
where it is difficult to distinguish between a pelvic focus 
and normal 131I-MIBG excretion in the urine. 
Ji[§_ULTS. 
(For details see Table 2 at the end of this chapter) 
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TOTALS: 
(See Pie diagram on next page) 
1. TOTAL NUMBER OF PATIENTS SCANNED: 28 
* 2. TOTAL NUMBER OF POSITIVE SCINTIGRAMS: 5 
3. TOTAL NUMBER OF NEGATIVE SCINTIGRAMS:18 
4. TOTAL NUMBER OF INDETERMINATE SCANS: 4 
(1 of which was positive on histology). 
5. SCINTIGRAPHY RESULT NOT AVAILABLE: 1 
* 6. HISTOLOGICALLY-PROVEN CASES: 11 
(1 of which had no scintigraphy result). 
SENSIT.IVITY: 50% 
TRUE POSITIVE TEST RESULTS/ALL PATIENTS WITH THE DISEASE38 
5 positive scans (group 2 above) out of 10 proven cases 
(group 6 above). One patient had no scintigraphy result and 
was therefore excluded. 
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PIE CHART 
RESULTS OF 1-131 MIBG SCINTIG RAP HY 
AT GSH 
INDETERMINATE 4 (14.3%) 
POSITIVE 5 ( 1 7. 9%) 
NO RECORD 1 (3.6%) 
NEGATIVE 18 (64.3%) 
32a 
S_P EC I F IC I_T Y : 10 i2Pk 3 8 
TRUE NEGATIVE TEST RESULTS/ALL PATIENTS WITHOUT THE DISEASE 
There were no false positive studies in this series. 
A._ P0SITIVE ____ 131_I __ -MIBG .... SCINTIGRAM.S 
(See Histogram 1) 
1. CLINICAL FEATURES 
. . .. 
AGE: 
Third decade: 3 patients 
Fifth decade: 2 patients 
SEX: 
Females:3 
Males: 2 
MAIN CLINICAL PROBLEM: 
Persistent hypertension: 2 
Abdominal masses: 2 (one of these had polycythemia) 
Paraplegia: 1 
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BLOOD PRESSURE: 
Persistent hypertension: 2 
Episodic hypertension: 2 
Normotensive: 1 
BLOOD PRESSURE RANGE: 120/80-180/110 mm Hg 
Of_ the _11._..£._at i en t s_ .. w.i_th ..... Pt:_oven phaeoch romoc_y_tCJill-=!_£ 
(See Histogram 2) 
Persistent hypertension: 5 
Labile hypertension: 3 
normotensive: 3 
FEATURES OF FAMILIAL PHAEOCHROMOCYTOMA: 
1 patient with evidence of cafe au lait spots and 
cutaneous neurofibromata presented with an abdominal 
swelling and was found to have bilateral phaeochromocytomas. 
2. BIOCHEMI_CAL. __ FINDI .. NG.S 
Normetadrenalin (NMA) and/or vanillylmandelic acid (VMA) 
levels in the urine were measured in 4 of the 5 patients 
with positive 131I-MIBG scintigraphy. 
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VALUES: 
NORMAL NMA= 0-5 micromol/24 hours 
1+= 5-10 micromol/24 hours 
2+= 10-20 micromol/24 hours 
3+= >20 micromol/24 hours 
NORMAL VMA= 10-40 micromol/24 hours 
1+= 40-100 micromol/24 hours 
2+= 100-200 micromol/24 hours 
3+= >200 micromol/24 hours 
RESULTS: 
NMA and/or VMA levels >1+: 4 patients 
No results: 1 patient 
Of. .... the _ 11 .. ....Pa ti en t.s .... w.i.t.h ...... h.i sto 1 o.9_i_c a 11._y_-proven .... di sea s_e: 
NMA and/or VMA levels >1+: 5 ••••••• 4 hypertensive 
Normal NMA and/or VMA 4 ••••••• 3 hypertensive 
No biochemical results: 2 
There was no correlation between the severity of the blood 
pressure and the urinary catecholamine and VMA levels. 
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3~_COMPUTERISED TOMOGRAPHY 
Positive CT scans: 4 
No result: 1 
Of ___ the_ 1) __ _p_a ti_ en t_s ____ w i __ t h ____ p r_o_v e n ___ ph a e o ch r o mo c y t oma :_ 
Positive CT scans: 9 
4. TYPES_ OF ___ PHAEOCHROMOCYTOM_A 
Malignant, metastastic phaeochromocytoma: 3 
Patient 1: Primary tumour in the thoracic sympathetic chain 
with metastatic lesions in 
hemipelvis and inferomedial to 
the skull, 
left kidney. 
spine ,right 
These lesions 
were found to be surgically inoperable and the patient was 
treated with 131r-MIBG. 
Patient 2: Primary tumour in the right adrenal with initial 
metastases in the region of the left kidney. After surgery 3 
further metastatic lesions were identified and the patient 
was treated with 131r-MI8G. 
Patient 3: Inoperable malignant tumour with multiple bone 
and soft tissue metastases. The primary tumour was not 
identified. 
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Benign, extra-adrenal pheaochromocytoma: 1 
This patient had an operable tumour situated in the region 
of the left kidney arising from the great vessels. 
Benign, bilateral (familial) phaeochromocytoma: 1 
This patient was found to have a right adrenal 
phaeochromocytoma and another tumour in the region of the 
lower pole of the left kidney. These were surgically 
removed. 
Of __ the _l) __ E_at_ients ____ with __ prov_en_diseas§!~. 
Benign, intra-adrenal tumours: 2 
One patient had a right adrenal tumour which was surgically 
removed. The other patient has been discussed above 
(familial disease). 
Benign, extra-adrenal tumours: 6 
Patient 1: This patient had a retrovesical tumour which was 
surgically removed. 
Patient 2: A tumour was located below the left renal hilum 
and was surgically removed. 
Patient 3 : An inoperable retroperitoneal tumour was 
discovered in this patient. 
Patient 4: Irresectable bilateral carotid body tumours were 
found in this patient. 
Patient 5: A left carotid body tumour was discovered which 
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HISTOLOGICALLY PROVEN CASES 
11 PATIENTS 
PERSISTENT HT EPISODIC HT (U) VMA/~Hv1A > 1 + CT POSITIVE 
was surgically removed. 
Patient 6: This patient has been discussed above (familial 
disease). 
Malignant, metastatic tumours: 3 
These patients have been discussed above. 
B • ___ NEGA.T I VE ___ 13_1 I_-M I_BG __ ,,sc IN_T_I GR.AMS 
(See Histogram 3) 
Eighteen patients had negative scintigraphy. The vast 
majority of these patients had no biochemical evidence for 
phaeochromocytoma only one patient had elevated 
catecholamines. Although CT was positive in 6 patients, 
these were found to have other disease on histology. 
1. CL I .. N I CAL .. __ F EA_T URES 
BLOOD PRESSURE: 
Persistent hypertension: 7 
Labile hypertension: 2 
Hypertension? type: 1 
The majority of these complained of headaches, palpitations 
and sweating. 
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Normotensive: 7 
Five of these presented with paroxysmal symptoms including, 
dizziness, sweating, palpitations and flushing. One was 
discovered to have bilateral adrenal masses while having a 
CT for abdominal pain, and the other presented with 
bilateral swelling of the neck. 
One patient had no available blood pressure recording. 
2 ·-·· BI OCHE.M I CAL] I ND_ING_S 
Normal VMA and/or NMA levels: 13 
Elevated NMA levels: 
phenothiazine No results available: 
1 •••••• ? 
4 
3 • .... COMP U_T ER I __ s E o .... TOM OGR_A PHY _ cc T L AND ___ UL T R_A SOU ND( U_SJ 
Positive CT scans: 6 
Negative CT and/or US scans: 8 
No available record: 4 
due to 
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PERSISTENT HT EPISODIC HT (U) VMA/N MA > 1 + CT POSITIVE 
HISTOGRAM 3 
C. I NOE TERM I NATE_ SC I NT I.G_RA.M_S 
(See HistogLam 4) 
FouL patients had indeteLminate scintigLams. 
1. CLINICAL __ FE_ATURES 
BLOOD PRESSURE: 
PeLsistent hypeLtension: 2 
Labile hypertension: 2 
Three of the 4 patients pLesented with sweating, 
palpitations and headaches. The fouLth was asymptomatic, 
hypertension being discovered on Loutine examination. 
2. BIOCHEMICAL __ F.I_NDING_S 
NMA and/or VMA levels >1+: 2 
NMA and/or VMA levels =1+: 1 
NoLmal NMA and/or VMA 1 
3. COME:_UTER I.S.ED ..... TOMOGR_A_PHY 
Positive CT scans: 1 
Negative CT scans: 2 
No available Lecord: 2 
One patient with seveLe hypeLtension and noLmal biochemistry 
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was found to have a phaeochromocytoma at surgery after 
having a positive CT scan. 
Of the three remaining patients one was found to have a 
renal artery stenosis while the other 2 were diagnosed as 
having essential hypertension. 
(See Histogram 5 for a comparison of patient features). 
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SUMMARY OF PATIENT FEATURES 
PERSISTENT HT 
cs:sJ NEG. 
28 PATIENTS 
EPISODIC HT (U) VMA/NMA > 1 + 
W/J INDETERMINATE 
HISTOGRAM 5 
CT POSITIVE 
~ PROVEN 
TA.BLE .... 2. 
R_ESULTS 
l!.g~_Sex __ C.l in i ca.l_..f.eature.s _________ Ca techo l~rt\J.D. .. ~.r::;-······-
1. 53/m Headache;Dizzy VMA(U) -
Persistent Ht TOT(U) -
B.P. 200/105 
2. 38/m Headache;Dizzy VMA(U) -
Palpitations NMA(U) -
Sweating;Flush 
Cafe au lait 
Labile Ht 
B.P. 240/170 
3. 51/m * Headache VMA(U) -
Palpitations TOT(U) -
Labile Ht 
B.P. 240/140 
4. 19/f * Headache;Flush NMA(U) ++ 
Sweating;SOB TOT(U) ++ 
B.P. 210/160 
5. 24/f Headache;Flush VMA(U) -
Dizzy;Nausea TOT(U) + 
Sweating 
Labile Ht 
B.P. 160/135 
6. 23/m Recurrent TIA .VMA(U) -
Persistent Ht 
7. 73/f Persistent Ht NR 
8. 18/m Headache NR 
Convulsions 
B.P. 130/90 
9. 34/m Asymptomatic NMA(U) + 
B.P. 160/110 TOT(U) ++ 
10. 63/m * Hoarse NMA(U) -
RUQ pain NMA(S) 
-
B.P. 140/80 
11. 47/m Palpitations VMA(U) -
Chest pain 
TIA 
B.P. 140/90 
..... M_IBG _________ Othe r 
Neg Neg CT 
Neg Neg CT 
Ind Pas CT 
NR Pas CT 
Ind RAS 
Neg Neg 
Neg NR 
Neg NR 
Ind Neg CT 
Neg PosCT 
Neg Pos CT 
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fill.EU..._Sex ____ Cl in i_ca_l _____ F_e at ur_e_s _____ Ca techo_l am i_ne s _____________ M I_BG ·--···- Ot_h_e r_ 
12. 23/f Palpitations 
Dizzy_ 
Sweating 
B.P. 140/80 
13. 25/f * Paramediast-
* inal mass 
B.P. 130/100 
14. 23/f * Headache;Dizzy 
15. 68/f 
16. 33/m 
* Sweating;Flush 
Palpitations 
Abdominal pain 
Abdominal mass 
Episodic Ht 
B.P. 140/110 
Sweating 
Palpitations 
Persistent Ht 
B.P. 200/120 
Malignant Ht 
B.P. 240/160 
17. 68/f * Abdominal pain 
Abdominal mass 
Persistent Ht 
B.P. 200/110 
18. 36/f Headache 
Palpitations 
Paroxysmal Ht 
B.P. 180/110 
19. 44/m * Abdominal mass 
20. 69/m 
21. 45/f 
* Cafe au lait 
Neurofibromatosis 
B.P. 120/80 
Medullary Ca 
of Thyroid 
Palpitations 
Headache;Flush 
Tremor;Sweating 
B.P. 130/90 
22. 25/f * Bilateral neck 
swellings 
B.P. 140/90 
VMA(U) -
TOT(U) -
NMA(U) ++ 
VMA(U) ++ 
NMA(U) +++ 
VMA(U) + 
NMA(U) + 
NMA/CR ++ 
NMA(U) ++ 
TOT(U) -
VMA(U) -
-VMA(U) -
VMA ( U) + + + 
NMA(U) -
NMA(U) -
NMA(U) -
NMA(U) + 
Nil 
Neg 
Pas 
Pas 
Ind 
Neg 
Neg 
Neg 
Pas 
Neg 
Neg 
Neg 
Neg CT 
Pas CT 
+B.S. 
Pas CT 
Neg CT 
Neg US 
Pos CT 
Neg CT 
Pas CT 
NR 
Neg CT 
Pas CT 
+ MRI 
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!!_g_e ~ex ____ C l_i n i ca l ___ Feature_s ________ Ca te_cho 1 am i_n_e s --··---· MI BG _____ Q_t.b_e_r:_ 
23. 19/f Abdominal pain 
Persistent Ht 
B.P. 220/160 
24. 69/f * Neck swelling 
Dysphasia 
Persistent Ht 
B.P. 180/100 
25. 70/m Abdominal pain 
Persistent Ht 
8.P. 170/110 
L.O.A.+ L.O.W. 
26. 26/f * Persistent Ht 
* B.P. 1 
27. 40/m NR 
28. 41/m * Sweating 
* Persistent Ht 
8.P. 180/110 
NMA(U) -
VMA(U) -
NMA(U) -
VMA(U) -
CAT(S) -
NMA(U) -
NMA(U) ++ 
NR 
NR 
* Histolagically-praven Phaeochromocytoma 
Neg 
Neg 
Neg 
Pas 
Neg 
Pas 
* 
* 
NR 
us 
Proven cases with positive .1311-MIBG scintigraphy 
No record available 
Ultrasound 
RAS Renal artery stenosis 
MRI Magnetic resonance imaging 
CT Computerised tomography 
B.S.Bane scan 
(U) Urinary 
(TOT) Total catecholamines 
B.P. Blood Pressure 
Ht Hypertension 
Neg CT 
Pas CT 
Pas CT 
Pas CT 
NR 
NR 
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TIA Transient Ischemic Attack 
RUQ Right Upper Quadrant 
LOA Loss of Appetite 
LOW Loss of Weight 
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CHAPTER FOUR 
D I_SCU_SS_I ON 
SENSITIVITY 
The low sensitivity of 50% obtained at Groote Schuur 
Hospital for 131I-MIBG scintigraphy differs significantly 
from results at other centres in the U.S.A. and Europe. 
Shapiro and his colleagues in Michigan4 report a sensitivity 
of 87% while Brown et al report a figure of 79% from a 
study at the Mayo Clinic6 and Ackery in Southampton5, a 
sensitivity of 89%. Baulieu et al working in Tours, France7 
report a sensitivity of 91% and Chatal of the French MIBG 
Study GroupB, a sensitivity of 91%. 
The reasons for this discrepancy are: 
1. PATIENT SELECTION: 
There were 4 false negative scans out o~ the 10 proven 
cases of phaeochromocytoma and 1 scan was indeterminate. The 
latter one will also be considered as a false negative for 
the purposes of this discussion. (One patient's scintigraphy 
result could not be found). 
Four of these 5 patients had normal biochemistry while 
the fifth had no biochemical investigations done. Four of 
these had no typical symptoms; 2 patients with carotid body 
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tumours presented with neck swellings, and the other 2, with 
atypical abdominal pain one of whom had an associated 
mass.The phaeochromocytomas in these patients were probably 
non-secretory and non-funcional and thus did not take up the 
1311-MIBG or secrete catecholamines. 
There have, however, been reports of uptake of 1311-
MIBG by "non-secreting"ll,"nonfunctiona1"12 "paragangliom-
as" or phaeochromocytomas. Khafagi et a112 demonstrated 
tumours in 2 patients , one with a carotid body tumour, 
despite normal urinary catecholamine and VMA levels. Smit et 
showed intense 1311-MIBG uptake in a carotid 
paraganglioma in the presence of modest elevation of urinary 
catecholamines (thought to be due to cardiac failure) and 
normal plasma concentrations. They concluded that the uptake 
of 1311-MIBG does not necessarily parallel catecholamine 
synthesis and secretion. 
Shapiro and his colleagues4 found that patients who 
did not exhibit typical symptoms of phaeochromocytoma and 
who had normal or borderline catecholamine levels "never 
harboured phaeochromocytomas." However, our experience has 
shown that patients with atypical symptoms and normal 
catecholamine levels do indeed harbour phaeochromocytomas, 
only these did not yield positive scintigraphy. However,this 
apparently contradictory 
definition. Shapiro 
finding may 
et al4 
be a mere 
specifically 
matter of 
excluded 
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nonfunctioning carotid body tumours from their series and 
what they 
patients 
termed "nonfunctioning paragangliomas". All our 
in the false negative group had normal 
biochemistry.I 
The fifth patient had typical symptomatology but normal 
biochemistry. This was possibly due to the fact that the 
catecholamine levels were measured during a period when the 
phaeochromocytoma was 
to have had elevated 
quiescent. This patient was reported 
catecholamine levels at the hospital 
from which he was referred but this could not be confirmed. 
Moreover, the 
compounded the 
urinary tract. 
2. BIOCHEMISTRY 
presence of an intravesical phaeochromocytoma 
problem as the 131I-MIBG is excreted via the 
In contrast to McEwan and his colleagues13 who showed 
no relationship between urinary catecholamine values and 
false negative 
patients with 
scintigraphic studies, at least 4 of the 5 
false negative studies at Groote Schuur 
Hospital had normal urinary catecholamine levels. 
We conclude that had we used criteria for selection based 
mainly upon a high index of clinical suspicion and raised 
catecholamine levels, our results would compare favourably 
with the studies mentioned above. The criteria used by 
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Shapiro et al4, outlined in Chapter Two would appear to 
provide too wide a margin for error. 
SPECIFICITY 
The specificity in our study was 100% i.e. there were 
no false positive studies. This compares favourably with the 
various series mentioned above. Most other series report 
false positives due to: uptake in other neuroendocrine 
tumoursB and in non-~ndocrine tumours39, and altered normal 
anatomy ,for example retention of radio-activity in a 
dilated renal pelvis mimicking a phaeochromocytomaB. The 
fact that our study was a comparatively small one may 
account for the absence of false positive images. 
TRUE POSITIVE_SC~NTIGRAMS 
BIOCHEMISTRY 
Four of the 5 patients with positive scintigraphy had 
significantly elevated urinary catecholamine metabolites (2+ 
or greater).(No results were available for the other 
patient). This is consistent with findings in other studies. 
McEwan et a113 found that positive 131I-MIBG images are 
associated with significantly increased levels of 
catecholamines and catecholamine metabolites in the urine. 
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Many studies have shown the impor-tance of ur-inar-y 
catecholamine and VMA concentr-ations in the assessment of 
found ur-inar-y phaeochr-omocytoma.Van Heer-den et a114 have 
metanephr-ines and VMA to be very sensitive diagnostic aids 
in phaeochr-omocytoma with accur-acy r-ates of 95% and 89% 
r-espectively. And all the patients in Acker-y's5 ser-ies with 
confir-med phaeochr-omocytoma had significantly elevated 
ur-inar-y catecholamine concentr-ations. Sixteen of their- 18 
patients had positive 1311-MIBG scintigr-ams. 
Our results are consistent with those of McEwan13 and 
Ackery5 in that we found that positive 1311-MIBG 
scintigraphy is associated with significantly elevated 
urinary catecholamine levels. It would appear that the 
increased uptake noted in the metabolically inactive tumours 
by Smitll and Khafagi12 are the exception to the rule and 
not a common occurrence. This would suggest that although 
the active uptake process does not necessar-ily accompany the 
processes of catecholamine production and secretion in the 
same tumour, that these pr-ocesses gener-ally occur- together 
in the same tumour. 
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CLINICAL PATTERNS 
Two of the 5 patients with positive scintigraphy 
presented with hypertension and symptoms associated with 
increased catecholamine release. Two presented with symptoms 
related to the mass effects of the phaeochromocytoma. One of 
these patients required frequent venesections for 
polycythemia which was subsequently discovered to be due to 
erythropoeitin-producing ,metastatic phaeochromocytoma.This 
is an extremely unusual presentation. The fifth patient 
presented with a paraplegia, 
spinal lesion. 
the result of a metastatic, 
Thus only 2 of our patients with positive scintigraphy 
presented with a typical clinical picture. It is less common 
for patients to present with the mass effects of the 
phaeochromocytoma and its metastases as was the case in 60% 
of our patients.A 
polycythemia as a 
tumour is very rare. 
Three of these 
patient 
result of 
patients 
p r e sent i n g w. i th secondary 
an erthropoeitin-producing 
presented in their third 
decade, at a somewhat younger age than the fourth and fifth 
decades when these patients usually present.13 Two of these 
were found to have metastatic, malignant disease. 
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TY_PES ___ O_F _PHAEOCHROMOC_YTOMA., 
1. MALIGNANT PHAEOCHROMOCYTOMA 
The three patients in this series with malignant, 
metastatic disease all had positive scintigraphy. This 
represents 60% of our patients with metabolically active 
disease, a very high figure when compared with the 10 - 15% 
incidence found in other studies.4;14 The 1311-MIBG proved 
to be a sensitive 
metastatic disease, 
investigation for the detection of 
and for assessing its progression, and 
repeat studies performed on 2 of these patients provided 
valuable information in this regard. 
In 2 of the patients bone metastases were confirmed on 
bone scintigraphy. The skeleton is the commonest site for 
phaeochromocytoma metastases.13 The other patient had 
multiple intra-abdominal lesions. On the basis of our study 
we would concur with Shapiro et al4 that 1311-MIBG 
scintigraphy appears to be superior to CT in the evaluation 
of metastastic disease as CT failed to show the metastatic 
lesions distant from the abdomen. 
The intra-abdominal lesions were detected by CT but 
131I-MIBG scintigraphy provided information regarding the 
functional nature of these lesions which the CT is unable to 
do. In addition, bone metastases were easily located and 
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confirmed on bone scintigraphy. Shulkin et have 
demonstrated metastatic lesions in the appendicular skeleton 
of patients with phaeochromocytoma by doing whole body 13 1 I-
MIBG scintigraphy. They found that focal lesions in the 
bones demonstr.ated by the 131I-MIBG scan are more specific 
for metastases than the bone scan. 
BENIGN EXTRAADRENAL TUMOUR 
One patient had a tumour in the region of the left 
adrenal which was found to involve the renal vessels. 
Histology showed an extraadrenal, functioning 
phaeochromocytoma. Both the CT and ultrasound investigations 
showed evidence of a mass lesion in the region of the left 
kidney. 
In this 
intraabdominal, 
false negative 
ser·ies CT 
extraadrenal 
CT scans in 
proved reliable in detecting 
tumours despite reports of 
other studies17;40. The CT also 
detected the presence of a bladder phaeochromocytoma which 
was difficult to evaluate due to the excretion of 131I-MIBG 
via this route. 
subtraction method 
However, 
used 
the 
by 
intravesical lesions was not used. 
Tc-99m DTPA 1311-MIBG 
Ackery5 to demonstrate 
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FAMILIAL PHAEOCHROMOCYTOMA 
One patient with neurofibromatosis was found to have 
benign,bilateral phaeochromocytomas. The patient had 
numerous cafe au lait spots and cutaneous neurofibromata. 
The incidence of phaeochromocytoma in patients with 
neurofibromatosis is reported as being ten times higher than 
in the general population.41 These tumours have been found 
to secrete adrenaline and noradrenaline in contrast to other 
phaeochromocytomas which secrete noradrenaline predominant-
ly. This is thought to be due to a link with Type 2a MEN 
syndrome.41 
Kalff et a141 have shown the value of screening 
patients with neurofibromatosis who present with 
hypertension. Our patient 
VMA levels were elevated. 
all phaeochromocytomas 
was normotensive but the urinary 
Pantoja42 believes that 5 -25% of 
occur in association with 
neurofibromatosis.Kalff41 found that all their patients had 
either intraadrenal and/or paraadrenal tumours. Our patient, 
who had right adrenal and left "ectopic" paraadrenal 
phaeochromocytomas, conformed to this pattern. 
will 
This 
be 
patient has 
required to 
a child with neurofibromatosis who 
undergo full investigation for 
phaeochromocytoma at a later stage. This is an important 
consideration as there is a known familial relationship with 
phaeochromocytomas. 
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TRUE NEGATIVE_SC~NTIGRAMS 
The 18 patients with true negative scintigraphy were 
found in all but one case to have no biochemical evidence of 
phaeochromocytoma. Six patients had positive CT scans but 
histology showed the presence of other disease. The large 
number of true negative scans is due to the fact that the 
criteria for patient selection did not exclude those with 
normal biochemistry. 
1!:!_g_R_APY.YITH ___ l 3_1 I .. -M.I __ BG 
Phaeochromocytomas are 
external beam radiotherapy13. 
resistant to chemotherapy and 
The 
that the 
rationale for the use of this form of therapy is 
1311-MIBG is taken up selectively by 
metabolically hyperactive malignant phaeochromocytoma. 
the 
The 
radiation dose to the tumour is therefore theoretically very 
high while the dose to the surrounding normal tissue is 
acceptably low. Wieland et al2 demonstrated a tumour to 
liver ratio of 680:1 after the administration of 1311-MIBG. 
Good metabolic uptake by the tumour tissue is a prerequisite 
for the trapping and retention of the approximately 20,000 
rads neccessary to relieve clinical symptoms which are 
secondary to increased catecholamine secretion. Sisson et 
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a143 believe that this radiation dose may result in the 
destruction of the tumour. 
Two of the patients with multiple, metastatic disease 
underwent courses of 1311-MIBG therapy. The response to the 
therapy was poor. Minimal alleviation of their symptoms 
residual occurred. One was readmitted within a year with 
active tumour and died the following year. The other was 
readmitted to hospital within 14 months of the treatment 
with a severe exacerbation of her symptoms. Scintigraphy 
showed new intraabdominal foci and 4 lesions were resected 
at surgery. 
Sisson et a143 treated 5 patients with malignant 
phaeochromocytoma with 2 to 4 doses of 3589-7289 MBq (97-
197mCi) of 1311-MIBG. Two patients showed improvement based 
upon the alleviation of symptoms, biochemistry and shrinkage 
in the size of their tumours. The other 3 patients showed no 
improvement. Significantly, 
bone metastases 
the patients who failed to 
in contrast to the others who respond had 
had mainly 
all under 
soft tissue involvement. The nonresponders were 
34 years of age. Both of our patients had 
extensive bone metastases and, moreover, both of them were 
under 32 years of age. 
A subsequent study performed by Sisson et a144 
demonstrated a favourable clinical or biochemical response, 
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or reduction in tumour size in 5 out of the 10 patients 
treated. Hoefnagel et treated 2 patients with 
malignant phaeochromocytoma with 3219-7881 MBg (87-213 mCi) 
doses of 1311-MIBG and noted relief of bone pain in one and 
radiological evidence of regression of lung 
the second. 
matastases in 
Fischer and Vetter45 treated 6 patients with malignant 
phaeochromocytoma with multiple doses of 2405-7770 MBg (65 -
210 mCi) of 1311-MIBG. In four of the patients either tumour 
progression or new metastases occurred. They conclude that 
although certain patients may improve clinically for a 
period of weeks to years,"the treatment is probably not 
curative." 
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CONCLUSION 
CONCLUSION 
. . 
THE_ ROLE __ OF __ 131 I -MI BG _I_N __ PHAEOCH_ROMOC_Y.__'.f._QJ1.A. 
The study at Groote Schuur Hospital has shown that 
131I-MIBG scintigraphy is a safe, reliable method for the 
diagnosis and localisation of metabolically active benign 
and malignant phaeochromocytoma provided that patient 
selection for the investigation is based upon significantly 
elevated levels of urinary and/or plasma catecholamines or 
their metabolites. This is the key to obtaining a high 
sensitivity. Exceptions may be made if the clinical 
suspicion of the disorder remains high despite normal 
biochemistry, or if the patient is on medication which is 
known to interfere with the biochemical tests. Methyldopa, 
guanethidine and reserpine are antihypertensives which come 
to mind. 1311-MIBG scintigraphy should not be used for the 
indiscriminate screening of patients who have hypertension 
with episodes of palpitations, sweating, headaches, but who 
have normal biochemistry. 
The value of 1311-MIBG as a therapeutic agent remains 
uncertain. The potential of a tumour-specific agent like 
l31r-MI8G is great, but there is little evidence to indicate 
that the treatment provides significant relief of symptoms. 
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And there is no evidence to suggest that this form of 
therapy is curative. There are, however, a number of problem 
areas which have yet to be elucidated, for the 
variations in tumour uptake in different 
example, 
patients and 
sometimes at different sites in the same patient; optimal 
doses and the frequency at which these may be administered; 
the differences in response in patients with bone metastases 
as compared with soft tissue secondary deposits. 
FUTURE PERSPECTIVES 
1231-MIBG has been found to be superior to 1311-MIBG as 
an imaging agent providing a far greater photon flux and 
permitting better delineation of lesions and the detection 
of smaller lesions. It also permits single photon emission 
tomography (SPECT) to be done which may further improve its 
efficacy. Moreover, 1231-MIBG has the advantage of a lower 
radiation dose to the patient. Furthermore, it permits the 
visualisation and quantitation 
adrenal medulla. 
1231-MIBG has the potential 
of uptake 
to become 
of the normal 
the agent of 
choice if the problems of expense and supply can be solved. 
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